Company intelligence
NEJM Group
Transforming tomorrow’s health care practice – with knowledge you need today.
About NEJM Group
NEJM Group brings together the people and products that have made the New England Journal of Medicine, NEJM AI, NEJM Evidence, NEJM Catalyst, NEJM Clinician, and NEJM CareerCenter leaders in providing the medical knowledge health care professionals need to deliver the best patient care. The goal of NEJM Group is to meet the rapidly growing demand for essential medical information and to disseminate that content in new ways to a broader global health care community than ever before. Our publications reach health care professionals around the globe — making connections between clinical science and clinical practice that advance medical knowledge, health care delivery, and patient outcomes. NEJM Group is a division of the Massachusetts Medical Society.
Verified activity
Signals from NEJM Group
6 published signals
Research & Knowledge
NEJM Group published a video explaining the TETON-2 trial investigating the use of treprostinil in patients with idiopathic pulmonary fibrosis.
Reported by NEJM Group
Research & Knowledge
NEJM Group published a full PARADIGM Research Summary in a phase 2 randomized trial comparing azacitidine-venetoclax therapy to induction chemotherapy in induction-eligible patients with AML.
Reported by NEJM Group
Research & Knowledge
NEJM Group published a new Clinical Practice article summarizing the management of pulmonary nodules, emphasizing nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with unnecessary procedures.
Reported by NEJM Group
Presence & Recognition
NEJM Group is hosting a virtual event featuring keynote speakers Geoff Crawford, Gene German, Isaac Kohane, and others discussing generative AI in guideline development and clinical decision-making.
Reported by NEJM Group
Research & Knowledge
NEJM Group published 18 articles simultaneously in NEJM and presented them at the European Society of Cardiology Congress in Munich.
Reported by NEJM Group
Research & Knowledge
NEJM Group published the results of the AZ-SWED randomized trial, which compared azithromycin to placebo in preschool-age children presenting to the emergency department with moderate-to-severe wheezing, showing no greater reduction in symptom severity than placebo.
Reported by NEJM Group